#BEGIN_DRUGCARD DB00994

# AHFS_Codes:
52:04.04
84:04.04

# ATC_Codes:
A01AB08
A07AA01
B05CA09
D06AX04
D09AA01
J01GB05
R02AB01
S01AA03
S01AA07
S02AA07
S03AA01

# Absorption:
Poorly absorbed from the normal gastrointestinal tract. Although only approximately 3% of neomycin is absorbed through intact intestinal mucosa, significant amounts may be absorbed through ulcerated or denuded mucosa or if inflammation is present.

# Biotransformation:
Neomycin undergoes negligible biotransformation after parenteral administration.

# Brand_Mixtures:
AK Spor liq (gramicidin + neomycin sulfate + polymyxin B sulfate)
AK Trol Suspension (dexamethasone + neomycin sulfate + polymyxin B sulfate)
Aminoderm Poudre (glycine + l-cysteine + neomycin sulfate + threonine)
Anaprime oph gel (flumethasone + neomycin sulfate + polymyxin B sulfate)
BNPH ont (bacitracin zinc + hydrocortisone acetate + neomycin sulfate + polymyxin B sulfate)
Bacitracin-neomycin polymyxin ont (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
Bacitracin-neomycin-polymixin ont (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
Biosol-M-Aquadrops liq (methscopolamine bromide + neomycin sulfate)
Calf scour bolus (atropine sulfate + calcium phosphate + hyoscyamine sulfate + kaolin + neomycin sulfate + pectin + sulfaguanidine + sulfathiazole + vitamin A)
Certreat Scours Oblets (chlortetracycline hydrochloride + neomycin sulfate + nicotinic acid + vitamin A + vitamin D)
Cicatrin Powder (bacitracin zinc + glycine + l-cysteine + neomycin sulfate + threonine)
Co-op pinkeye spray (gentian violet + neomycin sulfate)
Cortisporin (bacitracin zinc + hydrocortisone + neomycin sulfate + polymyxin B sulfate)
Derma-4 ont (neomycin sulfate + nystatin + thiostrepton (antibiotic of a streptomyces species) + triamcinolone acetonide)
Dioptrol ointment (dexamethasone + neomycin sulfate + polymyxin B sulfate)
Diosporin ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
Enterolyte (calcium chloride dihydrate + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
FML-Neo oph sus (fluorometholone + neomycin sulfate)
Forte topical suspension (hydrocortisone acetate + hydrocortisone sodium succinate + neomycin sulfate + penicillin g procaine + polymyxin B sulfate)
Kaobiotic bolus (kaolin + neomycin sulfate + pectin + sulfadiazine + sulfaguanidine + sulfamerazine + sulfathiazole)
Kaobiotic tab (kaolin + neomycin sulfate + pectin + sulfadiazine + sulfaguanidine + sulfamerazine + sulfathiazole)
Kenacomb (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
Keraplex spray (methyl violet + neomycin sulfate)
Lidecomb cream (fluocinonide + gramicidin + neomycin sulfate + nystatin)
Mastitis Care (neomycin sulfate + penicillin g potassium + polymyxin B sulfate + streptomycin sulfate)
Maxitrol (dexamethasone + neomycin sulfate + polymyxin B sulfate)
Mecomb Cream 0.1% (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
Mycitracin oph ont (bacitracin + neomycin sulfate + polymyxin B sulfate)
Neo Atropec 25 tab (aluminum hydroxide + atropine methylnitrate + kaolin + neomycin sulfate + pectin + sulfacetamide + sulfaguanidine)
Neo Atropec C tab (aluminum hydroxide + atropine methylnitrate + kaolin + neomycin sulfate + pectin + sulfacetamide + sulfaguanidine)
Neo Atropec tab (aluminum hydroxide + atropine methylnitrate + kaolin + neomycin sulfate + pectin + sulfacetamide + sulfaguanidine)
Neo Chlor Powder (neomycin sulfate + tetracycline hydrochloride)
Neo Darbazine Spansule Capsule no 1 (isopropamide iodide + neomycin sulfate + prochlorperazine maleate)
Neo Darbazine Spansule no 3 (isopropamide iodide + neomycin sulfate + prochlorperazine maleate)
Neo Oxymed Powder (neomycin sulfate + oxytetracycline hydrochloride)
Neo P.P.G. (neomycin sulfate + penicillin g potassium)
Neo Sulfa-E (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
Neo Sulfalyte Bolus (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
Neo Terramycin Soluble Powder (neomycin sulfate + oxytetracycline hydrochloride)
Neo-Cortef (hydrocortisone acetate + neomycin sulfate)
Neo-Medrol (methylprednisolone acetate + neomycin sulfate)
Neo-Medrol Acne Lotion (aluminum chlorohydrate + methylprednisolone acetate + neomycin sulfate + sulfur)
Neo-Oxytetracycline (neomycin sulfate + oxytetracycline hydrochloride)
Neo-Terramycin 50/50 premix (neomycin sulfate + oxytetracycline hydrochloride)
Neo-Tet pws (neomycin sulfate + oxytetracycline hydrochloride)
Neodecadron Eye Ear Solution 0.1% (dexamethasone phosphate + neomycin sulfate)
Neomix-Pamine Solution (methscopolamine bromide + neomycin sulfate)
Neopaste (aluminum hydroxide + calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine + sulfathiazole)
Neorease (neomycin sulfate + sulfamethazine + sulfathiazole)
Neosol M Aquadrops (methscopolamine bromide + neomycin sulfate)
Neospan Mastitis Treatment (neomycin sulfate + penicillin g potassium + polymyxin B sulfate + streptomycin sulfate)
Neosporin Eye-Ear Solution (gramicidin + neomycin sulfate + polymyxin B sulfate)
Neosporin Irrigating Solution (neomycin sulfate + polymyxin B sulfate)
Neosporin Ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
Neosporin Ophthalmic Ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
Neosporin antibiotic cream (gramicidin + neomycin sulfate + polymyxin B sulfate)
Neosulf (neomycin sulfate + sulfamethazine + sulfathiazole)
Neosulf Plus bolus (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
Neosulf bolus (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
Neosulpec (kaolin + neomycin + pectin + sulfaguanidine + sulfamethazine + sulfathiazole)
Neotet soluble concentrate (neomycin sulfate + oxytetracycline hydrochloride)
Neotetramed Powder (neomycin sulfate + tetracycline hydrochloride)
Neotopic ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
Neovast tabs (kaolin + neomycin sulfate + pectin + sulfadiazine + sulfaguanidine + sulfamerazine + sulfathiazole)
Neox (neomycin sulfate + oxytetracycline hydrochloride)
Ophtacin ophtalmic ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
Ophtacin-H ophtalmic ointment (bacitracin zinc + hydrocortisone acetate + neomycin sulfate + polymyxin B sulfate)
Optimyxin Plus Oto-opht GTTE (gramicidin + neomycin sulfate + polymyxin B sulfate)
Optiprime oph gel (neomycin sulfate + polymyxin B sulfate)
Optisone (neomycin + prednisolone)
Oribiotic ointment (bacitracin + lidocaine + neomycin sulfate + nystatin + triamcinolone acetonide)
Otizol HC liq (hydrocortisone acetate + lidocaine hydrochloride + neomycin sulfate)
P.T. Booster (calcium d-pantothenate + neomycin sulfate + nicotinic acid + pyridoxine hydrochloride + streptomycin sulfate + vitamin A + vitamin B1 + vitamin B12 + vitamin B2 + vitamin D3)
Panolog cream (neomycin sulfate + nystatin + thiostrepton [antibiotic of a streptomyces species] + triamcinolone acetonide)
Panolog ointment (neomycin sulfate + nystatin + thiostrepton [antibiotic of a streptomyces species] + triamcinolone acetonide)
Pinkeye Spray (gentian violet + neomycin sulfate)
Previte (neomycin sulfate + selenium sulfide + streptomycin sulfate + vitamin A + vitamin D + vitamin e + vitamin K1)
Proctosone ont (dibucaine hydrochloride + esculin + hydrocortisone acetate + neomycin sulfate)
Proctosone sup (dibucaine hydrochloride + esculin + hydrocortisone acetate + neomycin sulfate)
Ratio-Triacomb regular cream (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
Sandoz Cortimyxin (bacitracin zinc + hydrocortisone + neomycin sulfate + polymyxin B sulfate)
Scour Solution (methscopolamine bromide + neomycin sulfate)
Scour bolus plus (calcium carbonate + magnesium oxide + menadione sodium bisulfite + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + streptomycin sulfate + sulfamerazine + sulfamethazine + sulfanilamide + sulfathiazole + vitamin A + vitamin D)
Scour solution coop (methscopolamine bromide + neomycin sulfate)
Scour suspension (atropine sulfate + calcium phosphate + hyoscyamine sulfate + kaolin + neomycin sulfate + pectin + succinylsulfathiazole)
Scour treat liq (neomycin sulfate + sulfamethazine + sulfathiazole)
Scour-plug (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
Septomixine Forte (dexamethasone + halethazole tartrate + neomycin sulfate + polymyxin B sulfate + tyrothricin)
Solvaderm ointment (neomycin sulfate + nystatin + thiostrepton [antibiotic of a streptomyces species] + triamcinolone acetonide)
Spor-HC otic susp (hydrocortisone + neomycin sulfate + polymyxin B sulfate)
Sulectim plus scour boluses (calcium carbonate + magnesium oxide + menadione sodium bisulfite + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + streptomycin sulfate + sulfamerazine + sulfamethazine + sulfanilamide + sulfathiazole sodium + vitamin A + vitamin D)
Sulkamycin S Bolettes (neomycin sulfate + sulfamethazine)
Synalar Bi-otic solution (fluocinolone acetonide + neomycin sulfate + polymyxin B sulfate)
Theraderm cream (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
Tresaderm dermatologic solution (dexamethasone + neomycin sulfate + thiabendazole)
Triple sulfa plus neomycin (neomycin sulfate + sulfamerazine sodium + sulfamethazine sodium + sulfathiazole sodium)
Vetropolycin HC ont (bacitracin zinc + hydrocortisone acetate + neomycin sulfate + polymyxin B)
Vetropolycin ont (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
Viaderm KC Cream (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
Viaderm KC ont (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
Wound & Pinkeye Spray (gentian violet + neomycin sulfate)
bacitracin-neomycin-polymyxin oph ont (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
beef cattle vit ade premix medicated (neomycin sulfate + oxytetracycline hydrochloride + vitamin A + vitamin D3 + vitamin e)
dioptrol suspension (dexamethasone + neomycin sulfate + polymyxin B sulfate)
neo-chlor (neomycin sulfate + tetracycline hydrochloride)

# Brand_Names:
Biosol
Bykomycin
Endomixin
Fradiomycin
Fradiomycin Sulfate
Fraquinol
Lidamycin Creme
Myacine
Myacyne
Mycifradin
Mycifradin-N
Myciguent
Neo-Fradin
Neo-Mantle Creme
Neo-Rx
Neobiotic
Neobrettin
Neofracin
Neolate
Neomix
Nivemycin
Tuttomycin
Vonamycin Powder V

# CAS_Registry_Number:
1404-04-2

# ChEBI_ID:
7507

# Chemical_Formula:
C23H46N6O13

# Chemical_IUPAC_Name:
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
527750

# Description:
A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides.

# Dosage_Forms:
Dressing	Topical
Ointment	Ophthalmic
Solution / drops	Ophthalmic

# Drug_Category:
Aminoglycosides
Anti-Bacterial Agents
Antibiotics

# Drug_Interactions:
Cefotaxime	Increased risk of nephrotoxicity
Cefotetan	Increased risk of nephrotoxicity
Cefoxitin	Increased risk of nephrotoxicity
Ceftazidime	Increased risk of nephrotoxicity
Ceftriaxone	Increased risk of nephrotoxicity
Colistimethate	Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
Tacrolimus	Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Neomycin. Use caution during concomitant therapy.
Ticarcillin	Ticarcillin may reduce the serum concentration of Neomycin. Ticarcillin may inactivate Neomycin in vitro and the two agents should not be administered simultaneously through the same IV line.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-7.8

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Neomycin

# HET_ID:
CNY

# Half_Life:
2 to 3 hours

# InChI_Identifier:
InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1

# InChI_Key:
InChIKey=PGBHMTALBVVCIT-VCIWKGPPSA-N

# Indication:
Topical uses include treatment for superficial eye infections caused by susceptible bacteria (used in combination with other antiinfectives), treatment of otitis externa caused by susceptible bacteria, treatment or prevention of bacterial infections in skin lesions, and use as a continuous short-term irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters. May be used orally to treat hepatic encephalopathy, as a perioperative prophylactic agent, and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic E. coli (EPEC).

# KEGG_Compound_ID:
C00384

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
994

# Mechanism_Of_Action:
Aminoglycosides like neomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically neomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

# Melting_Point:
6 mg/mL (as sulfate form)

# Molecular_Weight_Avg:
614.6437

# Molecular_Weight_Mono:
614.312285588

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
1P87

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Neomycin Pathway	SMP00256

# PharmGKB_ID:
PA450608

# Pharmacology:
Neomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

# Predicted_LogP_Hydrophobicity:
-2.8

# Predicted_LogS:
-0.98

# Predicted_Water_Solubility:
6.47e+01 g/l

# Primary_Accession_No:
DB00994

# Protein_Binding:
Protein binding studies have shown that the degree of aminoglycoside protein binding is low and, depending upon the methods used for testing, may be between 0% and 30%.

# PubChem_Compound_ID:
8378

# PubChem_Substance_ID:
46505525

# RxList_Link:
http://www.rxlist.com/cgi/generic3/neomy.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00013

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Caswell No. 595
Neomycin B Sulfate
Neomycin Sulfate
Neomycin Sulphate
USAF CB-19

# Synthesis_Reference:
Not Available

# Toxicity:
LD50 = 200 mg/kg (rat). Because of low absorption, it is unlikely that acute overdosage would occur with oral neomycin. However, prolonged administration could result in sufficient systemic drug levels to produce neurotoxicity, ototoxicity and/or nephrotoxicity. Nephrotoxicity occurs via drug accumulation in renal proximal tubular cells resulting in cellular damage. Tubular cells may regenerate despite continued exposure and nephrotoxicity is usually mild reversible. Neomycin is the most toxic aminoglycoside agent, which is thought to be due to its large number of cationic amino groups. Otoxocity occurs via drug accumulation in the endolymph and perilymph of the inner ear causing irreversible damage to hair cells in the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing loss is followed by low frequency hearing loss. Further toxicity may cause retrograde degeneration of the auditory nerve. Vestibular toxicity may result in vertigo, nausea and vomiting, dizziness and loss of balance.

# Update_Date:
2013-02-08 16:19:49 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Neomycin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15332709	Gill AE, Amyes SG: The contribution of a novel ribosomal S12 mutation to aminoglycoside resistance of Escherichia coli mutants. J Chemother. 2004 Aug;16(4):347-9.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6103875	Eisenstein BI, Beachey EH, Ofek I: Influence of sublethal concentrations of antibiotics on the expression of the mannose-specific ligand of Escherichia coli. Infect Immun. 1980 Apr;28(1):154-9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
V00355

# Drug_Target_1_GenBank_ID_Protein:
43010

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
rpsL

# Drug_Target_1_Gene_Sequence:
>375 bp
ATGGCAACAGTTAACCAGCTGGTACGCAAACCACGTGCTCGCAAAGTTGCGAAAAGCAAC
GTGCCTGCGCTGGAAGCATGCCCGCAAAAACGTGGCGTATGTACTCGTGTATATACTACC
ACTCCTAAAAAACCGAACTCCGCGCTGCGTAAAGTATGCCGTGTTCGTCTGACTAACGGT
TTCGAAGTGACTTCCTACATCGGTGGTGAAGGTCACAACCTGCAGGAGCACTCCGTGATC
CTGATCCGTGGCGGTCGTGTTAAAGACCTCCCGGGTGTTCGTTACCACACCGTACGTGGT
GCGCTTGACTGCTCCGGCGTTAAAGACCGTAAGCAGGCTCGTTCCAAGTATGGCGTGAAG
CGTCCTAAGGCTTAA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
10094780	Arnold RJ, Reilly JP: Observation of Escherichia coli ribosomal proteins and their posttranslational modifications by mass spectrometry. Anal Biochem. 1999 Apr 10;269(1):105-12.
10209746	Toivonen JM, Boocock MR, Jacobs HT: Modelling in Escherichia coli of mutations in mitoribosomal protein S12: novel mutant phenotypes of rpsL. Mol Microbiol. 1999 Mar;31(6):1735-46.
12093756	Valle M, Sengupta J, Swami NK, Grassucci RA, Burkhardt N, Nierhaus KH, Agrawal RK, Frank J: Cryo-EM reveals an active role for aminoacyl-tRNA in the accommodation process. EMBO J. 2002 Jul 1;21(13):3557-67.
12244297	Tung CS, Joseph S, Sanbonmatsu KY: All-atom homology model of the Escherichia coli 30S ribosomal subunit. Nat Struct Biol. 2002 Oct;9(10):750-5.
12379845	Stark H, Rodnina MV, Wieden HJ, Zemlin F, Wintermeyer W, van Heel M: Ribosome interactions of aminoacyl-tRNA and elongation factor Tu in the codon-recognition complex. Nat Struct Biol. 2002 Nov;9(11):849-54.
12809609	Gao H, Sengupta J, Valle M, Korostelev A, Eswar N, Stagg SM, Van Roey P, Agrawal RK, Harvey SC, Sali A, Chapman MS, Frank J: Study of the structural dynamics of the E coli 70S ribosome using real-space refinement. Cell. 2003 Jun 13;113(6):789-801.
151587	Post LE, Arfsten AE, Reusser F, Nomura M: DNA sequences of promoter regions for the str and spc ribosomal protein operons in E. coli. Cell. 1978 Sep;15(1):215-29.
1552908	Timms AR, Steingrimsdottir H, Lehmann AR, Bridges BA: Mutant sequences in the rpsL gene of Escherichia coli B/r: mechanistic implications for spontaneous and ultraviolet light mutagenesis. Mol Gen Genet. 1992 Mar;232(1):89-96.
2477554	Allen PN, Noller HF: Mutations in ribosomal proteins S4 and S12 influence the higher order structure of 16 S ribosomal RNA. J Mol Biol. 1989 Aug 5;208(3):457-68.
320034	Funatsu G, Yaguchi M, Wittmann-Liebold B: Primary stucture of protein S12 from the small Escherichia coli ribosomal subunit. FEBS Lett. 1977 Jan 15;73(1):12-7.
6989816	Post LE, Nomura M: DNA sequences from the str operon of Escherichia coli. J Biol Chem. 1980 May 25;255(10):4660-6.
7556101	Urlaub H, Kruft V, Bischof O, Muller EC, Wittmann-Liebold B: Protein-rRNA binding features and their structural and functional implications in ribosomes as determined by cross-linking studies. EMBO J. 1995 Sep 15;14(18):4578-88.
8844851	Kowalak JA, Walsh KA: Beta-methylthio-aspartic acid: identification of a novel posttranslational modification in ribosomal protein S12 from Escherichia coli. Protein Sci. 1996 Aug;5(8):1625-32.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
308

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
13606

# Drug_Target_1_Name:
30S ribosomal protein S12

# Drug_Target_1_Number_of_Residues:
123

# Drug_Target_1_PDB_ID:
1P87

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00164	Ribosomal_S12

# Drug_Target_1_Protein_Sequence:
>30S ribosomal protein S12
ATVNQLVRKPRARKVAKSNVPALEACPQKRGVCTRVYTTTPKKPNSALRKVCRVRLTNGF
EVTSYIGGEGHNLQEHSVILIRGGRVKDLPGVRYHTVRGALDCSGVKDRKQARSKYGVKR
PKA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Cryo-EM studies suggest that S12 contacts the EF-Tu bound tRNA in the A-site during codon-recognition. This contact is most likely broken as the aminoacyl-tRNA moves into the peptidyl transferase center in the 50S subunit

# Drug_Target_1_SwissProt_ID:
P0A7S3

# Drug_Target_1_SwissProt_Name:
RS12_ECOLI

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
11.49

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17131180	Roy U, Nair D: Biodiversity of organotin resistant Pseudomonas from west coast of India. Ecotoxicology. 2007 Mar;16(2):253-61. Epub 2006 Nov 28.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17553640	Brown JM, Cowley KD, Manninen KI, McNeil MM: Phenotypic and molecular epidemiologic evaluation of a Nocardia farcinica mastitis epizootic. Vet Microbiol. 2007 Nov 15;125(1-2):66-72. Epub 2007 May 6.
17875999	Wachino JI, Shibayama K, Kurokawa H, Kimura K, Yamane K, Suzuki S, Shibata N, Ike Y, Arakawa Y: Plasmid-mediated novel m1A1408 methyltransferase, NpmA, for 16S rRNA found in clinically isolated Escherichia coli resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother. 2007 Sep 17;.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
>16S rRNA sequence
AAATTGAAGAGTTTGATCATGGCTCAGATTGAACGCTGGCGGCAGGCCTAACACATGCAA
GTCGAACGGTAACAGGAAACAGCTTGCTGTTTCGCTGACGAGTGGCGGACGGGTGAGTAA
TGTCTGGGAAACTGCCTGATGGAGGGGGATAACTACTGGAAACGGTAGCTAATACCGCAT
AACGTCGCAAGACCAAAGAGGGGGACCCTCGGGCCTCTTGCCATCGGATGTGCCCAGATG
GGATTAGCTTGTTGGTGGGGTAACGGCTCACCAAGGCGACGATCCCTAGCTGGTCTGAGA
GGATGACCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGG
GGAATATTGCACAATGGGCGCAAGCCTGATGCAGCCATGCCGCGTGTATGAAGAAGGCCT
TCGGGTTGTAAAGTACTTTCAGCGGGGAGGAAGGGAGTAAAGTTAATACCTTTGCTCATT
GACGTTACCCGCAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAG
GGTGCAAGCGTTAATCGGAATTACTGGGCGTAAAGCGCACGCAGGCGGTTTGTTAAGTCA
GATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATCTGATACTGGCAAGCTTGAGTCTC
GTAGAGGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACC
GGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCA
AACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGTCGACTTGGAGGTTGTGCC
CTTGAGGCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGCCTGGGGAGTACGGCCGCA
AGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAAT
TCGATGCAACGCGAAGAACCTTACCTGGTCTTGACATCCACGGAAGTTTTCAGAGATGAG
AATGTGCCTTCGGGAACCGTGAGACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGA
AATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGGTCCGGC
CGGGAACTCAAAGGAGACTGCCAGTGATAAACTGGAGGAAGGTGGGGATGACGTCAAGTC
ATCATGGCCCTTACGACCAGGGCTACACACGTGCTACAATGGCGCATACAAAGAGAAGCG
ACCTCGCGAGAGCAAGCGGACCTCATAAAGTGCGTCGTAGTCCGGATTGGAGTCTGCAAC
TCGACTCCATGAAGTCGGAATCGCTAGTAATCGTGGATCAGAATGCCACGGTGAATACGT
TCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTGGGTTGCAAAAGAAGTAGGT
AGCTTAACCTTCGGGAGGGCGCTTACCACTTTGTGATTCATGACTGGGGTGAAGTCGTAA
CAAGGTAACCGTAGGGGAACCTGCGGTTGGATCACCTCCTTA

# Drug_Target_2_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_2_General_References:
10194318	Gu XR, Gustafsson C, Ku J, Yu M, Santi DV: Identification of the 16S rRNA m5C967 methyltransferase from Escherichia coli. Biochemistry. 1999 Mar 30;38(13):4053-7.
12948628	Martin JF, Barreiro C, Gonzalez-Lavado E, Barriuso M: Ribosomal RNA and ribosomal proteins in corynebacteria. J Biotechnol. 2003 Sep 4;104(1-3):41-53.
1764510	Srivastava AK, Schlessinger D: Structure and organization of ribosomal DNA. Biochimie. 1991 Jun;73(6):631-8.
8177168	Gutell RR, Larsen N, Woese CR: Lessons from an evolving rRNA: 16S and 23S rRNA structures from a comparative perspective. Microbiol Rev. 1994 Mar;58(1):10-26.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
883

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
16S rRNA

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
1EMI

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
rRNA + mRNA + Amino Acids = Polypeptide

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
In prokaryotes, the 16S rRNA is essential for recognizing the 5' end of mRNA and hence positioning it correctly on the ribosome. The 16S rRNA has a characteristic secondary structure in which half of the nucleotides are base-paired. The 16S rRNA sequence has been highly conserved and is often used for evolutionary and species comparative analysis.

# Drug_Target_2_SwissProt_ID:
Not Available

# Drug_Target_2_SwissProt_Name:
Not Available

# Drug_Target_2_Synonyms:
16S ribosomal ribonucleic acid

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00994
